COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00751452
Recruitment Status : Unknown
Verified January 2011 by University Hospital, Clermont-Ferrand.
Recruitment status was:  Recruiting
First Posted : September 12, 2008
Last Update Posted : January 19, 2011
Information provided by:
University Hospital, Clermont-Ferrand

Brief Summary:
determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Condition or disease
Benign Disease

Detailed Description:

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).

Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Time Perspective: Prospective
Official Title: Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Study Start Date : April 2008
Estimated Primary Completion Date : September 2009
Estimated Study Completion Date : September 2009


Primary Outcome Measures :
  1. Citrullinemia (weekly) [ Time Frame: weekly ]

Secondary Outcome Measures :
  1. Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Inclusion Criteria:

  • 0 to 18 years
  • allogeneic bone marrow transplantation for malignant or benign disease
  • affiliation to French sécurité sociale
  • parent's consent

Exclusion Criteria:

  • severe gastro-intestinal involvement before transplant
  • previous digestive surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00751452

Layout table for location contacts
Contact: Lacarin Patrick

Layout table for location information
Etienne MERLIN Recruiting
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Layout table for investigator information
Principal Investigator: Merlin Etienne, Dr University Hospital, Clermont-Ferrand
Layout table for additonal information
Responsible Party: Merlin Etienne, CHU Clermont-Ferrand Identifier: NCT00751452    
Other Study ID Numbers: CHU-0040
First Posted: September 12, 2008    Key Record Dates
Last Update Posted: January 19, 2011
Last Verified: January 2011
Keywords provided by University Hospital, Clermont-Ferrand:
Allogeneic bone marrow transplantation
Intestinal damage
Graft versus Host Disease
0 to 18 years old
Additional relevant MeSH terms:
Layout table for MeSH terms
Urea Cycle Disorders, Inborn
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases